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Th   e central theme of this year’s meeting was very clear: 
genomic technologies are now entering clinical labora-
tories across the world on a scale that would have seemed 
unimaginable even a year ago.
Th  e technology that has made the greatest impact in 
the past 12 months has been exome sequencing, which 
captures only the protein-coding regions of the genome. 
Despite only exploring about 1% of the sequence in a 
genome, it is a cost-eﬀ  ective approach for patients with 
severe diseases, in whom the majority of causal mutations 
are expected to disrupt protein sequence.
Exome sequencing is now being applied to patients on 
a massive scale - multiple presenters, including Han 
Brunner (Nijmegen Centre for Molecular Life Sciences) 
presented exome data from dozens or even hundreds of 
individuals - and that scale is set to increase exponentially. 
Margriet von Kogelenberg (Wellcome Trust Sanger 
Institute) described the UK-based Deciphering Develop-
mental Disorders (DDD) project, which is currently 
recruiting 12,000 patients with developmental delay for 
array comparative genomic hybridization analysis and 
exome sequencing.
Genomics has unquestionably accelerated the 
discovery of the mutations underlying severe Mendelian 
diseases. Dozens of novel disease-associated genes were 
presented at the meeting, and there is a widespread (and, 
I suspect, justiﬁ  ed) view that a substantial majority of 
Mendelian disease genes will be identiﬁ   ed within the 
next 18 to 24 months.
In addition, the technology is already moving beyond 
the research domain and into the world of clinical 
diagnostics. Most of the research projects presented here 
generate results that ﬂ  ow (via a process of validation) 
back to clinicians and patients. Th  e task of assembling 
systems for translating genomic data into clinical 
interpretation was thus a key topic of discussion.
Th  is meeting provided an eloquent counterpoint to 
media reports on the ‘failure’ of the Human Genome 
Project: medicine is clearly being transformed by 
genomics, with rare diseases at the vanguard of that 
transformation. Th  ere has never been a more exciting 
time to be working in the ﬁ  eld.
The interpretation challenge
Although this meeting illustrated the acceleration of 
mutation discovery by next-generation sequencing, it is 
worth noting two key challenges to translating large-scale 
sequence data into clinical utility raised in presentations 
and informal discussions.
Firstly, there is the diﬃ   culty of answering a straight-
forward question: has a mutation seen in a patient with 
disease been previously reported in another individual 
with a similar phenotype? Unfortunately, as those work-
ing in the ﬁ  eld can testify, obtaining this information is 
frustrating: there is currently no single, comprehensive, 
open-access database of known disease-causing muta-
tions. Instead, knowledge is split between a variety of 
resources of varying comprehensiveness, usability and 
access policies. Th  e lack of a reliable global database of 
known disease mutations remains one of the most 
embarrassing failures of modern human genetics.
Two presenters discussed independent approaches to 
addressing this failure: Donna Maglott (National Center 
for Biotechnology Information) discussed the relatively 
new ClinVar database, and Joanna Amberger (Johns 
Hopkins University) discussed the modernization of the 
venerable Online Mendelian Inheritance in Man (OMIM) 
resource. Both eﬀ   orts are admirable, as are other 
independent ventures in the same ﬁ   eld, such as 
mutaDATABASE and the Human Variome Project. Yet I 
and other attendees were left wondering which of these 
resources, if any, will ultimately provide the one-stop 
shop for high-conﬁ  dence human disease mutations that 
is so sorely needed in the genomic era; certainly none do 
so currently.
Another challenge was pervasive in informal conversa-
tions at the meeting, but only rarely addressed in 
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should be applying when conﬁ  rming that a novel muta-
tion is in fact disease-causing? Several speakers, including 
James Lupski (Baylor College of Medicine), noted that 
many published disease-causing mutations are demon-
strably erroneous; it is clear that historical standards for 
proving causation have been inadequate. Th  e  Mendelian 
genomics community needs stringent guidelines for estab-
lishing signi  ﬁ    cant ﬁ  ndings, similar to those developed by 
researchers working on genome-wide association studies 
of complex traits.
Yet at this meeting there was no clear consensus on 
what such guidelines should look like, and there were 
worrying signs that false mutations from exome studies 
may already be creeping into the literature: for instance, 
many researchers seem to regard a de novo protein-
altering mutation as having a very high probability of 
disease causation, when in fact such variants are carried 
by about 50% of healthy individuals. It is to be hoped that 
eminent researchers and journal editors will work 
together to develop strong and transparent standards for 
the ﬁ  eld; otherwise, in an era of cheap exome sequencing, 
even a low false positive rate will rapidly swamp the 
literature with spurious ﬁ  ndings.
Moving beyond the exome
Despite the current focus on exome sequencing, 
geneticists appreciate the importance of making sense of 
genetic variants that fall outside protein-coding regions: 
a non-trivial fraction of the mutations underlying rare 
diseases, and variants underlying the majority of the risk 
of common complex disorders, fall in the ‘dark matter’ 
outside the exome. Th  is meeting provided reasons for 
both optimism and pessimism about the future of 
interpreting genetic variation within that dark matter.
Th   e optimism comes from the unraveling of the func-
tional map of human non-coding DNA through the 
application of new genome-scale approaches. Many of 
these approaches have been pioneered in the context of 
the massive ENCODE project, which is coming to 
fruition this year. Lucas Ward (Massachusetts Institute 
of Technology) presented data on behalf of ENCODE 
showing that many of the variants implicated in 
complex diseases either disrupt or create DNA 
sequences that are bound by transcription factors. Non-
coding mutations can also underlie Mendelian 
disorders, of course: Cornelis Albers (Wellcome Trust 
Sanger Institute) described a wonderful genetic 
detective story in which a thrombocytopenia syndrome 
turned out to be caused by compound heterozygosity 
for a rare null allele and a more common non-coding 
polymorphism in the RBM8A gene, which encodes a 
vital component of the exon-junction complex involved 
in RNA processing.
Th   e pessimism comes from data suggesting that global 
prediction of the functional impact of non-coding 
variants will be challenging even with genome-scale data. 
Joseph Hiatt (University of Washington) described an 
elegant experimental approach to explore the impact of 
mutations in enhancer elements, which showed that the 
vast majority of changes to enhancer elements have small 
or undetectable impacts on gene expression because of 
functional redundancy. Although Hiatt’s approach 
provides an experimental method for exploring the 
eﬀ  ects of variation in enhancer elements, it also indicates 
that de novo prediction of these eﬀ  ects on the basis of 
sequence data alone will be extremely challenging.
Th   e rate at which functional annotation of non-coding 
DNA is progressing is astonishing, and it is clear that 
many profound biological insights are emerging from the 
ENCODE project. However, it is equally clear that we 
remain far from a general model accurately predicting 
the functional impact of genetic variation in non-coding 
DNA.
Data: to return or not to return?
Th  e ﬁ  nal session of the meeting focused on ethical and 
policy issues. A strong theme in this session, and indeed 
throughout the meeting, was a familiar dilemma: should 
research participants be given access to ‘incidental 
ﬁ   ndings’ related to disease risk but irrelevant to the 
primary research question - for instance, a mutation in 
the BRCA1 breast cancer gene identiﬁ  ed in a study on 
intellectual disability - and if so, how should this be done?
Opinions on this issue varied wildly among meeting 
participants; although this session by no means resolved 
the debate, it provided useful food for thought. Jonathon 
Berg (University of North Carolina) presented a strategy 
for binning genetic ﬁ   ndings into categories related to 
their risk and clinical utility, and argued that the majority 
of genetic variants in a patient’s genome lack clinical 
utility and should be excluded from medical records. 
Caroline Wright (Wellcome Trust Sanger Institute) 
discussed the data return strategy for the DDD project, 
under which ‘clinically pertinent’ ﬁ  ndings related to the 
patient’s primary diagnosis will be returned, but 
incidental ﬁ  ndings will not.
Hopefully data return policies will ultimately be driven 
by the desires of participants rather than the views of 
ethicists. Unfortunately we currently know surprisingly 
little about participant expectations, but this is set to 
change: the DDD is currently coordinating an open 
survey at the GenomEthics website, of the views of 
research participants and other stakeholders, in which I 
would encourage readers to participate.
Th  e informed uncertainty in this session was a ﬁ  tting 
end to the meeting, which showed both that genomics is 
already transforming the diagnosis of rare diseases, and 
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issues remains to be resolved by the community. I look 
forward to seeing how the situation has changed at this 
meeting in 2013.
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